semaglutide cancer cases GLP-1 use linked to lower breast incidence in large cohort study glp-1 cancer risk No Increased

This only needs to be done before your first injection with each new pen

230 cases with both +2.2 times more likely 15% of cases 6.96% (2,589 cases) 120 cases with both +2.1 times more likely 8% of cases 3.75% (1,417 cases) 147 cases with both +2.1 times more likely 10% of cases 4.69% (1,752 cases) 688 cases with both +2.1 times more likely 46% of cases 21.59% (13,471 cases) Purple/blue lips Please login or create a free account to see statistics filtered on Tarry black stools and Purple/blue lips

Clinical data suggests tirzepatide produces slightly greater average weight loss than semaglutide, but the difference is not enormous, and some patients respond better to one medication than the other

For those exploring the broader peptide landscape, peptides for weight loss beyond GLP-1 agonists offer complementary approaches